Loading...

News List

全球首创降糖新药华堂宁获批

2022-10-09


全球首创降糖新药华堂宁获批

北京,2022年10月9日——拜耳宣布,国家药品监督管理局批准糖尿病全球首创新药华堂宁(多格列艾汀片),用于单独用药,或者在单独使用盐酸二甲双胍血糖控制不佳时,与盐酸二甲双胍联合使用,配合饮食和运动改善成人2型糖尿病患者的血糖控制。华堂宁是拜耳与华领医药在糖尿病治疗领域达成的推广的产品合作,是全球范围内首个获批的葡萄糖激酶激活剂类药物。


Pre: Haihe Pharmaceuticals' Paclitaxel Oral Solution China Marketing Authorization Application Officially Accepted

Next: Huatangning, the world's first new hypoglycemic drug was approved

We would like to use cookies to better understand your use of this website, which will help improve your experience on future visits to the website. You can change this setting in your browser settings. For more information about the use of cookies, please refer to our Privacy Policy.